NCT07240467: ASCENT-BC

Bovis Calculus Stativus Treat Acute Cerebral Ischemic Stroke With Impaired Consciousness

Not yet recruiting Phase 2, PHASE3 Last updated 18 December 2025

What this trial tests

Phase 2, PHASE3 trial testing Bovis Calculus Stativus (BCS) in Acute Ischemic Stroke AIS in 220 participants. Not yet recruiting.

Timeline

15 December 2025

Primary endpoint
15 December 2028

15 December 2028

Quick facts

Lead sponsor	Xiang Luo
Phase	Phase 2, PHASE3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	220
Start date	15 December 2025
Primary completion	15 December 2028
Estimated completion	15 December 2028

Drugs / interventions tested

• Bovis Calculus Stativus (BCS) — full drug profile →
• Placebo

Conditions studied

• Acute Ischemic Stroke AIS — all drugs for Acute Ischemic Stroke AIS →
• Impaired Consciousness — all drugs for Impaired Consciousness →

Sponsor

Xiang Luo — full company profile →

Who can join

18 and older, any sex, with Acute Ischemic Stroke AIS or Impaired Consciousness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute ischemic stroke (AIS) is a severe and life-threatening condition, with 35% of AIS patients experiencing impaired consciousness upon admission within 24 hours of onset. Previous studies indicated that patients with impaired consciousness at the onset of stroke have a higher incidence of stroke-related complications, particularly cerebral edema and pneumonia, as well as higher in-hospital and three-month mortality rates. The etiology of impaired consciousness in AIS is complex: ischemic damage to reticular activating system of the brainstem can directly lead to cell necrosis and result in impaired consciousness. Furthermore, secondary pathological changes following AIS, such as excitatory amino acid toxicity, oxidative stress, free radical production, and cascading inflammatory responses, can indirectly worsen impaired consciousness. Therefore, impaired consciousness at the onset of AIS is the result of cellular damage under multiple pathophysiological mechanisms. Developing neuroprotective drugs with multiple targets is key to effectively improving adverse outcomes related to impaired consciousness in AIS. However, there is currently a lack of treatment specifically aimed at improving impaired consciousness at the onset of AIS.

Cultivated Bovine Bezoar (Bovis Calculus Stativus, BCS) combines the advantages of pharmacological similarity to natural bovine by adding components such as deoxycholic acid, cholic acid, and composite calcium bilirubin to fresh bovine bile. It is rich in various trace elements and amino acids and is a compound medication that can exert neuroprotective effects through multiple pathways and targets. In traditional Chinese medicine, it has long been used to treat various consciousness disorder-related diseases, including stroke. The various components of in vitro cultivated bezoar are also widely used in clinical research for various neurological diseases.The above evidence fully demonstrates that BCS is an optimal treatment for impaired consciousness in stroke.

The goal of this clinical trial is to learn if Bovis Calculus Stativus works to treat acute cerebral ischemic stroke with impaired consciousness. It will also learn about the safety of Bovis Calculus Stativus. The main questions it aims to answer are:

1. Does Bovis Calculus Stativus treat and alleviate consciousness disorders in patients with acute cerebral infarction accompanied by impaired consciousness ？
2. What medical problems do participants have when taking Bovis Calculus Stativus?

Researchers will compare Bovis Calculus Stativus to a placebo (a look-alike substance that contains no drug) to see if Bovis Calculus Stativus works to treat acute cerebral ischemic stroke with impaired consciousness.

Participants will:

1. receive treatment with Bovis Calculus Stativus (or placebo) for 5 days.
2. Take an in-person or telephone follow-up within 90 days after the acute stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.